Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy
- 19 May 2020
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 191 (1) , 44-51
Abstract
Summary: Patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL) have limited options for salvage, and checkpoint blockade therapy (CBT) has little efficacy. Usage in solid malignancies suggests that CBT sensitises tumours to subsequent chemotherapy. We performed the first analysis of CBT on subsequent NHL treatment. Seventeen North American centres retrospectively queried records. The primary aim was to evaluate the overall response rate (ORR) to post‐CBT treatment. Secondary aims included progression‐free survival (PFS), duration of response (DOR) and overall survival (OS). Fifty‐nine patients (68% aggressive NHL, 69% advanced disease) were included. Patients received a median of three therapies before CBT. Fifty‐three (90%) discontinued CBT due to progression. Post‐CBT regimens included chemotherapy (49%), targeted therapy (30%), clinical trial (17%), transplant conditioning (2%) and chimeric antigen receptor T cell (CAR‐T) therapy (2%). The ORR to post‐CBT treatment was 51%, with median PFS of 6·1 months. In patients with at least stable disease (SD) to post‐CBT, the median DOR was significantly longer than to pre‐CBT (310 vs. 79 days, P = 0·005) suggesting sensitisation. Nineteen patients were transplanted after post‐CBT therapy. Median overall survival was not reached, nor affected by regimen. Prospective trials are warranted, as this may offer R/R NHL patients a novel therapeutic approach.Keywords
Funding Information
- American Cancer Society (MRSG-14-052-01-LIB)
This publication has 27 references indexed in Scilit:
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent LymphomaJournal of Clinical Oncology, 2019
- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyJournal of Clinical Oncology, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2019
- Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United StatesJournal of Medical Economics, 2018
- PD-1 expression and clinical PD-1 blockade in B-cell lymphomasBlood, 2018
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- Checkpoint blockade in Hodgkin and non-Hodgkin lymphomaBlood Advances, 2017
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 studyBlood, 2017
- Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer.Journal of Clinical Oncology, 2017
- Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapiesCancer Management and Research, 2013